|
Fig. 4 Plasma proteomic predictors of new MRI-detectable lesions. (a) Violin plot of normalized protein expression (NPX) of GDF-15 for patients with more than 5 new CCM-MRI lesions and less than 5 lesions over 2 years of trial period; and ROC curve analysis for predictive model using GDF-15 (derived from OLINK® cardiovascular panel) as a predictor to discriminate between patients with more than 5 new CCM-MRI lesions or less than 5 lesions over 2 years trial period. (b) Violin plot of normalized protein expression (NPX) of FLT3L, CXCL9, FGF-21 and CDCP1 for patients with more than 5 new CCM-MRI lesions and less than 5 lesions over 2 years of trial period. (c) ROC curve analysis for predictive CCM progression using a panel of predictors, FLT3L, CXCL9, FGF-21 and CDCP1 (derived from OLINK® inflammation panel) to discriminate between patients with more than 5 new CCM-MRI lesions or less than 5 lesions over 2 years trial period.